Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavodelpar in Fatty Acid Oxidation Disorders
NCT03833128Phase 1Completed
- Sponsor
- Reneo Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of mavodelpar in Long Chain Fatty Acid Oxidation Disorders (LC-FAOD) (3 arms), sponsored by Reneo Pharmaceuticals. Primary endpoint: Adverse Events at 12 weeks. Started Apr 2019; status: completed.
02
Drugs
mavodelpar
03
Conditions
Long Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Beyond the preview
Go deeper on NCT03833128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833128.